First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

  1. Justicia-Lirio, P.
  2. Tristán-Manzano, M.
  3. Maldonado-Pérez, N.
  4. Barbero-Jiménez, C.
  5. Cortijo-Gutiérrez, M.
  6. Pavlovic, K.
  7. Molina-Estevez, F.J.
  8. Muñoz, P.
  9. Hinckley-Boned, A.
  10. Rodriguez-Madoz, J.R.
  11. Prosper, F.
  12. Griñán-Lison, C.
  13. Navarro-Marchal, S.A.
  14. Panisello, C.
  15. Muñoz-Ballester, J.
  16. González-Sierra, P.A.
  17. Herrera, C.
  18. Marchal, J.A.
  19. Martín, F.
Journal:
Molecular Therapy Nucleic Acids

ISSN: 2162-2531

Year of publication: 2024

Volume: 35

Issue: 4

Type: Article

DOI: 10.1016/J.OMTN.2024.102308 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus